GT BIOPHARMA, INC. Interest Income, Other
GT BIOPHARMA, INC. (GTBP) reported Interest Income, Other of $58.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Income Statement › Other Income
us-gaap:InterestIncomeOther · last filed 2026-08-14
- GT BIOPHARMA, INC. interest income, other for the quarter ending 2026-06-30 was $58.00K, a 52.63% increase year-over-year.
- GT BIOPHARMA, INC. interest income, other for the quarter ending 2026-03-31 was $67.00K, a 109.38% increase year-over-year.
- GT BIOPHARMA, INC. interest income, other for the quarter ending 2025-12-31 was $17.00K, a 71.19% decline year-over-year.
- GT BIOPHARMA, INC. interest income, other for the quarter ending 2025-09-30 was $36.00K, a 62.50% decline year-over-year.
- GT BIOPHARMA, INC. interest income, other for fiscal 2025 was $123.00K, a 69.40% decline from fiscal 2024.
- GT BIOPHARMA, INC. interest income, other for fiscal 2024 was $402.00K, a 48.46% decline from fiscal 2023.
- GT BIOPHARMA, INC. interest income, other for fiscal 2023 was $780.00K, a 167.12% increase from fiscal 2022.
- GT BIOPHARMA, INC. interest income, other for fiscal 2022 was $292.00K, a 668.42% increase from fiscal 2021.
| Period end | Interest Income, Other 3 month | Interest Income, Other 6 month | Interest Income, Other 9 month | Interest Income, Other 12 month |
|---|---|---|---|---|
| 2026-06-30 | $58.00K 10-Q · filed 2026-08-14 | $125.00K 10-Q · filed 2026-08-14 | $142.00K derived: sum of 3 quarters · filed 2026-08-14 | $178.00K derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $67.00K 10-Q · filed 2026-05-15 | $84.00K derived: sum of 2 quarters · filed 2026-05-15 | $120.00K derived: sum of 3 quarters · filed 2026-05-15 | $158.00K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $17.00K derived: 10-K 12 month − 10-Q/A 9 month · filed 2026-03-02 | $53.00K derived: sum of 2 quarters · filed 2026-03-06 | $91.00K derived: sum of 3 quarters · filed 2026-08-14 | $123.00K 10-K · filed 2026-03-02 |
| 2025-09-30 | $36.00K 10-Q/A · filed 2026-03-06 | $74.00K derived: sum of 2 quarters · filed 2026-08-14 | $106.00K 10-Q/A · filed 2026-03-06 | $165.00K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $38.00K 10-Q · filed 2026-08-14 | $70.00K 10-Q · filed 2026-08-14 | $129.00K derived: sum of 3 quarters · filed 2026-08-14 | $225.00K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $32.00K 10-Q · filed 2026-05-15 | $91.00K derived: sum of 2 quarters · filed 2026-05-15 | $187.00K derived: sum of 3 quarters · filed 2026-05-15 | $292.00K derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $59.00K derived: 10-K 12 month − 10-Q/A 9 month · filed 2026-03-02 | $155.00K derived: sum of 2 quarters · filed 2026-03-06 | $260.00K derived: sum of 3 quarters · filed 2026-03-06 | $402.00K 10-K · filed 2026-03-02 |
| 2024-09-30 | $96.00K 10-Q/A · filed 2026-03-06 | $201.00K derived: sum of 2 quarters · filed 2026-03-06 | $343.00K 10-Q/A · filed 2026-03-06 | $523.00K derived: sum of 4 quarters · filed 2026-03-06 |
| 2024-06-30 | $105.00K 10-Q/A · filed 2026-03-06 | $247.00K 10-Q/A · filed 2026-03-06 | $427.00K derived: sum of 3 quarters · filed 2026-03-06 | $643.00K derived: sum of 4 quarters · filed 2026-03-06 |
| 2024-03-31 | $142.00K 10-Q · filed 2025-05-15 | $322.00K derived: sum of 2 quarters · filed 2025-05-15 | $538.00K derived: sum of 3 quarters · filed 2025-05-15 | $758.00K derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $180.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-21 | $396.00K derived: sum of 2 quarters · filed 2025-02-21 | $616.00K derived: sum of 3 quarters · filed 2025-02-21 | $780.00K 10-K · filed 2025-02-21 |
| 2023-09-30 | $216.00K 10-Q · filed 2024-11-14 | $436.00K derived: sum of 2 quarters · filed 2024-11-14 | $600.00K 10-Q · filed 2024-11-14 | |
| 2023-06-30 | $220.00K 10-Q · filed 2024-08-14 | $384.00K 10-Q · filed 2024-08-14 | ||
| 2023-03-31 | $164.00K 10-Q · filed 2024-05-15 | |||
| 2022-12-31 | $292.00K 10-K · filed 2024-03-26 | |||
| 2021-12-31 | $6.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $38.00K derived: sum of 2 quarters · filed 2023-03-30 | $38.00K 10-K · filed 2023-03-30 | |
| 2021-09-30 | $32.00K 10-Q · filed 2021-11-10 | $32.00K 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |